-
IntroducedMar 11, 2025
-
Passed Senate
-
Passed House
-
Signed into Law
Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and the administration of that treatment.
Last Action See all actions
Senate • Apr 24, 2025: Vote taken in committee
Latest Bill Text See all bill texts
Summary/Bill Text
Comments on SB 2308
Tweets
Whip Lists
Sponsors
Votes
Actions
- Apr 24, 2025 | Senate
- Considered in public hearing
- Vote taken in committee
- Apr 23, 2025 | Senate
- Scheduled for public hearing on . . . 04/23/2025
- Considered in public hearing
- Testimony taken in committee
- Left pending in committee
- Mar 25, 2025 | Senate
- Read first time
- Referred to Health & Human Services
- Mar 11, 2025 | Senate
- Received by the Secretary of the Senate
- Filed
Bill Texts